Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Invivyd Inc IVVD

Healthcare Biotechnology
Invivyd, Inc. is a commercial-stage company, which is engaged in delivering antibody-based therapies. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The Company delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2 (COVID-19). Its PEMGARDA is the Company’s first mAb in a planned series of innovative mAb candidates designed to keep pace with SARS-CoV-2 viral evolution. Its VYD2311 is optimized for neutralization potency against recent SARS-CoV-2 lineages such as BA.2.86 and JN.1. The Company also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.


NDAQ:IVVD - Post by User

Invivyd Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(77)
•••
Post by Humaniston Feb 22, 2022 9:19am
70 Views
Post# 34449631

ADGI:TO ANALYZE DATA FROM TRIALS GLOBALLY/RESULTS END MARCH

ADGI:TO ANALYZE DATA FROM TRIALS GLOBALLY/RESULTS END MARCH BRIEF-Adagio Therapeutics Outlines Strategic Initiatives For Co's ADG20 Program
 
Published by  Reuters 2022 Feb 22, 13:46

Feb 22 (Reuters) - Adagio Therapeutics Inc : * ADAGIO THERAPEUTICS INC - OUTLINED STRATEGIC INITIATIVES FOR CO'S ADG20 PROGRAM * ADAGIO THERAPEUTICS - IN Q1 OF 2022, CO PLANS TO ANALYZE CLINICAL DATA FROM GLOBAL PHASE 2/3 CLINICAL TRIALS FOR PREVENTION AND TREATMENT OF COVID-19 * ADAGIO THERAPEUTICS INC - ANALYSIS WILL BE AVAILABLE IN LATE MARCH AND CO EXPECTS THESE DATA WILL INFORM NEXT STEPS FOR ADG20 Source text for Eikon: Further company coverage: ((reuters.briefs@thomsonreuters.com;))
 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities